A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

This study compares a combination of BL-B01D1 — a new antibody-drug conjugate targeting cancer proteins EGFR and HER3 — plus osimertinib versus osimertinib alone as first-line treatment for people with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 or older with locally advanced or metastatic NSCLC that cannot be removed surgically or treated with radical radiation - Your tumor has a known EGFR-sensitizing mutation (confirmed by tumor or blood testing) - You have at least one measurable tumor on imaging - You have a good performance status (ECOG 0 or 1) - You have not received prior systemic treatment for advanced disease **You may NOT be eligible if...** - You have had prior EGFR-targeted therapy or other systemic treatment for advanced NSCLC - You have uncontrolled brain metastases - You have significant heart, lung, or liver problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.